Skip to main content

“I am a Canadian, free to speak without fear, free to worship in my own way, free to stand for what I think right, free to oppose what I believe wrong, or free to choose those who shall govern my country. This heritage of freedom I pledge to uphold for myself and all mankind.” ~~ John G. Diefenbaker

FRASER INSTITUTE -- Canada’s comparatively weak intellectual property protections limit access to life-saving drugs


Because Canada’s protection of intellectual property in the life sciences—including biology and biochemistry—lags behind other industrialized countries, Canadian patient access to potentially life-saving biologic medicines is comparatively limited, finds a new study released today by the Fraser Institute, an independent, non-partisan Canadian public policy think-tank.

 

“Cutting-edge biologic drugs are treating previously untreatable conditions, often with fewer adverse effects, improving the health of patients and saving lives worldwide,” said Kristina Acri, associate professor of economics at Colorado College, senior fellow at the Fraser Institute and author of Biologics and Biosimilars: A Primer.

 

According to the study, as of December 2018 (the latest month of comparable data), Canada has approved only 10 “biosimilars,” which are versions of biologic drugs, compared to 15 in the United States, 20 in Australia and 62 in the European Union.

 

Biologic drugs are produced from (or contain elements of) living organisms. They are more complicated—and more expensive—to develop, produce, distribute and dispense than other medicines.

 

Subsequently, the ability of drug companies to protect their intellectual property—for example, through data exclusivity, which essentially prevents competing firms from producing generic versions of the drugs for a period of time—is essential for incentivizing the development of biologics, particularly because biopharmaceutical innovations are easily copied and sold by competitors.

 

Unfortunately, Canada’s current intellectual property laws are weak compared to laws in other jurisdictions including the U.S. and EU. For example, Canada has one of the shortest terms of data exclusivity for pre-clinical and clinical trials.

 

“If Canadian policymakers want to improve access to state-of-the-art drugs in Canada, they must strengthen protections for intellectual property,” Acri said.

Labels:

Comments

Post a Comment

Popular posts from this blog

BC’s Forestry Decline Is a Policy Failure, Not a Market Reality -- Forestry Critic Calls for Accountability and Urgent Policy Reset

Conservative Party of BC Forestry Critic, and Kamloops - North Thompson MLA,  Ward Stamer As the Truck Loggers Association convention begins today, BC Conservative Forestry Critic Ward Stamer says British Columbia’s forestry crisis is the result of government mismanagement, not market forces, and that an urgent policy reset is needed to restore certainty, sustainability, and accountability. “For generations, forestry supported families and communities across BC,” said Stamer.  “Today, mills are closing, contractors are parking equipment, and families are being forced to leave home, not because the resource is gone, but because policy has failed.” Government data shows timber shipment values dropped by more than half a billion dollars in the past year, with harvest levels falling by roughly 50 per cent in just four years. At the same time, prolonged permitting timelines, unreliable fibre access, outdated forest inventories, and rising costs have made long-term planning impossib...
Post a Comment
Read more

BC cannot regulate, redesign, and reinterpret its way to a stable forestry sector. Communities need clear rules, predictable timelines, and accountability for results.

Photo credit:  Atli Resources LP   BC’s Forestry Crisis Continues with Closure of Beaver Cove Chip Facility   As industry leaders, Indigenous partners, and contractors gather this week at the BC Natural Resources Forum in Prince George, the gap between government rhetoric and reality could not be clearer. Just hours after the Eby government once again touted reconciliation, certainty, and economic opportunity under DRIPA, Atli Chip Ltd, a company wholly owned by the ’Na̱mg̱is First Nation, announced it is managing the orderly closure of its Beaver Cove chip facility. The closure comes despite public tax dollars, repeated government announcements, and assurances that new policy frameworks would stabilize forestry employment and create long-term opportunity in rural and coastal British Columbia. “British Columbians are being told one story, while communities are living another,” said Ward Stamer, Critic for Forests. “This closure makes it clear that announcement...
Post a Comment
Read more

Eby government signs another land-use agreement, as they say one thing and do another, during DRIPA chaos

While promising to fix DRIPA, the Eby government continues to quietly sign binding land-use agreements that fundamentally alter how Crown land is governed in British Columbia. On January 15, 2026, the government signed four ministerial orders advancing the Gwa’ni Land Use Planning Project with the ’Na̱mg̱is First Nation, amending the Vancouver Island Land Use Plan and changing how more than 166,000 hectares of Crown land can be accessed, developed, and managed. “This is Land Act reform by stealth,” said Critic for Indigenous Relations Scott McInnis. “British Columbians already rejected these changes once. In 2024, public backlash forced the NDP to pull its Land Act amendments. Instead of listening, this government has gone underground, signing individual deals behind closed doors, just like we’ve already seen in places such as Squamish, Teẑtan Biny, and across Northwest BC.” “The Premier admits DRIPA ( the Declaration on the Rights of Indigenous Peoples Act) is creating ...
Post a Comment
Read more

Labels

Show more